Analysis of mortality risk following receipt of implantable cardioverter defibrillators in patients with and without heart failure
Journal
Journal of Cardiology
Date Issued
2020
Author(s)
Abstract
Background: Patients covered by the Taiwan National Health Insurance (NHI) program are eligible to receive an implantable cardioverter defibrillator (ICD) if diagnosed with heart failure (HF) or were at high risk of sudden cardiac death. The study was designed to evaluate the prognoses for ICD recipients with respect to contributory risks. Methods: ICD recipients (N = 2138) from Taiwan's NHI database, for the 11-year period 2004–2014 were identified and assigned to no heart failure (NHF, n = 978) or heart failure groups (HF, n = 1160). The mortality rates were reported and survival trends were compared between groups. Results: The mean age of these patients was 61.8 ± 15.2 years and 69% were men. The HF group was older (65 vs. 58 years) and had significantly more comorbidities. Pharmaceutical and medical resource utilization was also uniformly higher within the HF group. The 30-day (1.8%) and 1-year (18.4%) mortality rates among the HF patients were 3–4 times higher than in the NHF group (log rank p = 0.006 and p < 0.001, respectively). A coexistent major diseases score was consistently associated with a progressive mortality risk in ICD recipients overall. Conclusions: Of those receiving ICDs, the prognosis for HF patients is poorer than for those in the NHF group which most likely reflects the fact that the HF patients were generally older with more complicated medical conditions as evident by the association between multiple major organ dysfunction and an increased risk of death. ? 2020 Japanese College of Cardiology
SDGs
Other Subjects
2,4 thiazolidinedione derivative; alpha adrenergic receptor blocking agent; alpha glucosidase inhibitor; angiotensin receptor antagonist; antiarrhythmic agent; antihypertensive agent; atropine; beta adrenergic receptor blocking agent; bicarbonate; calcium channel blocking agent; digitalis glycoside; dipeptidyl carboxypeptidase inhibitor; diuretic agent; dopamine; epinephrine; fibric acid derivative; hydroxymethylglutaryl coenzyme A reductase inhibitor; insulin derivative; noradrenalin; oral antidiabetic agent; prescription drug; sulfonylurea; vasopressin; adult; aged; Article; cardiomyopathy; cohort analysis; comorbidity; controlled study; disease association; emergency care; female; follow up; health care utilization; heart arrhythmia; heart failure; heart failure with reduced ejection fraction; hematothorax; hemopericardium; hospitalization; human; insulin treatment; kidney disease; major clinical study; male; mortality rate; mortality risk; national health insurance; pericardiocentesis; pneumothorax; prescription; prognosis; secondary prevention; sudden cardiac death; survival; survival rate; Taiwan; adverse device effect; epidemiology; heart failure; implantable cardioverter defibrillator; middle aged; mortality; risk factor; Aged; Defibrillators, Implantable; Female; Heart Failure; Humans; Male; Middle Aged; Prognosis; Risk Factors; Taiwan
Publisher
Japanese College of Cardiology (Nippon-Sinzobyo-Gakkai)
Type
journal article